Literature DB >> 28972457

Oncologic Effectiveness and Safety of Bursectomy in Patients with Advanced Gastric Cancer: A Systematic Review and Updated Meta-Analysis.

Luigi Marano1, Karol Polom2, Alberto Bartoli1, Alessandro Spaziani1, Raffaele De Luca3, Laura Lorenzon4, Natale Di Martino5, Daniele Marrelli2, Franco Roviello2, Giampaolo Castagnoli1.   

Abstract

Purpose/Aim: In the past few decades some researchers have questioned whether bursectomy for gastric cancer is essential from an oncological point of view and no consistent recommendations have been proposed. The aim of this systematic review with meta-analysis is to investigate the oncologic effectiveness and safety of bursectomy for the treatment of advanced gastric cancer patients.
MATERIALS AND METHODS: We planned and performed this systematic review and meta-analysis in accordance with Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement and Cochrane Handbook for Systematic Reviews of Intervention.
RESULTS: Overall, four studies with a total of 1,340 patients met inclusion criteria. The pooled hazard ratio for overall survival between the bursectomy versus nonbursectomy groups was [HR = 0.85, 95% CI 0.66-1.11, p =.252]. Interestingly, the pooled HR between the two groups in serosa-positive cases subgroup, showed a significant improvement of overall survival rate in favor of bursectomy [HR = 0.72, 95% CI 0.73-0.99, p <.05].
CONCLUSIONS: Bursectomy represents a surgical procedure that might be able to improve overall survival in serosa positive gastric cancer patients. However, a definitive conclusion could not be made because of the studies' methodological limitations. This meta-analysis points to the urgent need of high quality, large-scaled, clinical trials with short- as well as long-term evaluation comparing bursectomy with non bursectomy procedures, in a controlled randomized manner, helping future researches and establishing a modern and tailored approach to gastric cancer.

Entities:  

Keywords:  D2 lymphadenectomy; bursectomy; gastrectomy; gastric cancer; meta-analysis; prognosis

Mesh:

Year:  2017        PMID: 28972457     DOI: 10.1080/08941939.2017.1355942

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  5 in total

1.  The role of bursectomy in the surgical management of gastric cancer: a meta-analysis and systematic review.

Authors:  Konstantinos Perivoliotis; Ioannis Baloyiannis; Dimitrios Symeonidis; Konstantinos Tepetes
Journal:  Updates Surg       Date:  2020-06-03

Review 2.  Evolution of treatment in gastric cancer- a systematic review.

Authors:  Sangram K Panda; Pradyumna K Sahoo; Sunil K Agarwala; Tim Houghton T; Prathamesh Panchakshari Chandrapattan; Vikas Sankar K; Ramkishan Nag
Journal:  J Egypt Natl Canc Inst       Date:  2022-03-21

3.  Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer.

Authors:  Gerasimos N Douridas; Andreas Fountoulakis; John Souglakos; Sofia Gourtsoyianni; Louiza Vini; Georgia Levidou; Theodoros Liakakos; Christos Agalianos; Christos Dervenis; Maria Angeliki Kalogeridi; Ioannis Karavokyros; Anna Koumarianou; Panteleimon Kountourakis; Georgios Oikonomopoulos; Panagiota Economopoulou; Joseph Sgouros; Spiros N Sgouros; Konstantinos Stamou; Charikleia Triantopoulou; Dimitrios Zacharoulis; Nikolaos Gouvas; Evangelos Xynos
Journal:  Updates Surg       Date:  2020-02-28

Review 4.  Complete Mesogastric Excisions Involving Anatomically Based Concepts and Embryological-Based Surgeries: Current Knowledge and Future Challenges.

Authors:  Sergii Girnyi; Marcin Ekman; Luigi Marano; Franco Roviello; Karol Połom
Journal:  Curr Oncol       Date:  2021-11-22       Impact factor: 3.677

5.  Efficiency of complete omentectomy in patients with resectable gastric cancer: a meta‑analysis and systematic review.

Authors:  Akao Zhu; Guang Yin; Xinchun Liu; Wencheng Kong; Yu Zhang; Yuqiang Shan; Rongchao Ying; Jian Zhang; Chunhua Zhou
Journal:  BMC Gastroenterol       Date:  2021-09-14       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.